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Abstract
Identifying the causes of dementia is important in the search for
effective preventative and treatment strategies. The concept of
mild cognitive impairment (MCI), as prodromal dementia, has been
useful but remains controversial since in population-based studies
it appears to be a limited predictor of progression to dementia.
Recognising the relative contribution of neurodegenerative and
vascular causes, as well as their interrelationship, may enhance
predictive accuracy. The concept of vascular cognitive impairment
(VCI) has been introduced to describe the spectrum of cognitive
change related to vascular causes from early cognitive decline to
dementia. A recent review of this concept highlighted the need for
diagnostic criteria that encompass the full range of the VCI
construct. However, very little is known regarding the mildest stage
of VCI, generally termed ‘vascular cognitive impairment, no
dementia’ (VCIND). Whether mild cognitive change in the context
of neurodegenerative pathologies is distinct from that in the
context of cerebrovascular diseases is not known. This is key to the
definition of VCIND and whether it is possible to identify this state.
Distinguishing between vascular (that is, VCIND) and non-vascular
(that is, MCI) cognitive disorders and determining how well each
might predict dementia may not be possible due to the overlap in
pathologies observed in the older population. Here, we review the
concept of VCIND in an effort to identify recent developments and
areas of controversy in nosology and the application of VCIND for
screening individuals at increased risk of dementia secondary to
vascular disease and its risk factors.
Introduction
A better understanding of dementia, including its causes,
underlying pathophysiological processes and earliest
possible identification, has become a major public health
priority. Changes in cognition associated with age are
complex, especially with regard to distinguishing usual from
pathological brain ageing. Multiple and often intertwined
pathological factors, including atrophy, neurodegeneration,
inflammation, stroke and genetic-related factors, cause
dementia [1]. Here, we explore the link between vascular
disease, cognitive decline and dementia risk. Given the
relatively high proportion of dementia attributable to possibly
reversible midlife vascular causes [2], it has been suggested
that vascular risk manipulation may result in up to a 50%
reduction in the forecasted dementia prevalence rate in
individuals who are 65 years old or older [3,4]. Vascular risk
factors for dementia may also contribute to impairments
observed in the pre-clinical stage of cognitive decline. This
has raised questions regarding (a) whether vascular disease
can predict cognitive change and dementia risk in otherwise
non-impaired individuals and (b) the duration and possible
reversal of cognitive symptoms and dementia depending on
vascular disease manipulation and treatment. The aim of this
review is to describe the current understanding of the division
between pre-clinical cognitive impairment in the context of
vascular disease versus the absence of vascular disease. The
focus will be on the term ‘vascular cognitive impairment, no
dementia’ (VCIND), an umbrella term that broadly encom-
passes cognitive deficits associated with vascular disease
which fall short of a dementia diagnosis, in order to determine
whether within the context of this condition there is a pre-
clinical state linked to a high risk of dementia progression.
Age-related changes in the vascular system
Ageing in the developed world is associated with changes in
the vascular system which result in atherogenesis, increased
pulse pressure and increased risk of developing vascular
disease as a consequence of a direct effect on the vascular
system (for example, arterial hypertension and vasculitis) or
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indirect metabolic and haemodynamic effects secondary to
other disorders (for example, diabetes, congestive heart
failure and obesity) [5]. Vascular disease can reduce cerebral
perfusion, causing oxidative stress and neurodegeneration
[6]. Vascular disease has also been reported to accelerate
atrophy and result in white matter abnormalities, asympto-
matic infarct, inflammation and reduced glucose metabolism,
cerebral blood flow and vascular density [5,7]. Such patho-
logical changes have been associated with not only dementia
of the vascular type but also Alzheimer disease (AD) [8,9].
The mechanisms by which vascular disease and its risk
factors cause pathology and how such changes impact
cognitive function are incompletely understood but are
thought to depend on age, disease co-morbidity, lifestyle and
genetic susceptibility and predisposition. An important
question is whether different vascular disease factors can be
separated from each other and from the effect of ageing itself
in order to identify their unique impact on cognitive function.
A more complete understanding of the relationship between
vascular disease, cognitive decline and dementia risk will
have important implications in identifying vulnerable
population subgroups and a potential treatment target.
Classification systems of early cognitive
change
Age-related cognitive change can be placed along a con-
tinuum from normal to severely demented, with intermediate
stages of cognitive decline. To date, there is no consensus
on where boundaries between disease and non-disease lie, if
such a definite boundary exists. Rather than a strict dichoto-
misation, the determination of impairment may instead be
based on the likelihood or probability that ageing is not occur-
ring in accordance with normative expectations. Furthermore,
classification systems of cognitive change themselves raise
questions regarding the level of cognitive and functional
dysfunction used to reliably categorise individuals and those
risk factors apart from ageing itself that contribute to mild and
severe cognitive change.
Mild cognitive impairment
The term mild cognitive impairment (MCI) broadly defines an
intermediate state of cognitive decline, predominately linked
to impaired memory function, which is thought to be
predictive of dementia, primarily AD. Various definitions have
been proposed in the literature, each with differences in
focus (for example, age-associated change versus patho-
logical decline) and diagnostic criteria (for example, memory
versus non-memory impairment) [10-14]. As a possible tool
for identifying individuals at increased risk of dementia, MCI is
an important concept. Indeed, in clinical samples, individuals
with a case diagnosis of the anmestic subtype of MCI (A-
MCI) [15-17] have been found to progress to dementia at a
rate of 10% to 15% per year compared with a progression
rate of only 1% to 2% in normal controls [18,19]. In contrast,
in the general population, the positive predictive validity of A-
MCI is poor [19]. Many incident dementia cases are found to
be excluded from an A-MCI case diagnosis, and of persons
with A-MCI, many remain stable or revert to normal cognitive
status at follow-up [10]. These findings are consistent across
all MCI definitions (for example, amnestic versus non-
amnestic and single- versus multiple-domain MCI) [19].
No MCI criteria can be recommended for population screen-
ing of individuals at high dementia risk [20]. This raises a
number of questions regarding the precision and utility of
current diagnostic criteria and what the best indicators of
dementia risk are and whether these are being captured in
current diagnostic methods. Poor predictability possibly
results from limitations in case findings due to a lack of
clinical judgement and inflexibility in operationalisation of
criteria when a diagnosis of MCI is made outside the clinical
setting. However, it has been suggested that MCI
predictability may be improved through consideration of the
underlying pathogenesis of cognitive decline [21]. Sub-
classification of MCI with and without co-morbid vascular
disease may therefore be important for discriminating
individuals at high versus low dementia risk in the general
population.
Although the fact is not always explicitly stated in MCI-
defining criteria, an MCI case diagnosis is usually made
following the exclusion of individuals with psychiatric and
vascular co-morbidity [10,12,22]. As such, the association
between vascular disease and MCI is not widely studied.
Where vascular disease has been evaluated in the context of
MCI, no clear pattern between vascular disease and incident
MCI or between vascular disease, MCI and risk of dementia
progression has been found. An increased risk of incident
MCI has been associated with elevated midlife blood
pressure [23], elevated total cholesterol level [23], history of
coronary artery bypass grafting [24], stroke [25] and midlife
hypertension [21] in some, but not other [26], studies. Only
atrial fibrillation and low folate levels have been associated
with an increased risk of dementia progression from MCI
[27]. Inconsistencies in conclusions possibly result from
differences in patient sources (for example, clinic- versus
population-based), type of impairment (for example, narrow
[A-MCI] versus global measures of cognitive impairment as
captured in the term ‘cognitive impairment, no dementia’
[CIND]), definitions of disease and measurement of vascular
factors over varying time frames and with instruments of
different sensitivities (for example, subjective report versus
objective measure). To better identify the link between
vascular disease and cognitive impairment, the term vascular
cognitive impairment (VCI) was introduced [9,28-32].
Cognitive impairment and vascular disease
VCI refers to cognitive decline attributable to vascular
disease. However, unlike MCI (which is a narrow term
capturing a pre-clinical form of dementia), VCI encompasses
individuals affected with any degree of cognitive decline
caused by or associated with vascular disease and its riskfactors. As such, the level of impairment in VCI ranges in
severity from mild to vascular dementia (VaD) or mixed VaD,
in which cerebrovascular and AD pathologies co-occur. Calls
for more specific staging have recently led to further sub-
classification of VCI to capture vascular disease-related
impairment not fulfilling criteria for dementia. This stage is
defined using the term VCIND and has been further
subdivided to include specific terms for pre-clinical impair-
ment, including vascular MCI (V-MCI), MCI of vascular type,
pre-clinical VCI, vascular pre-dementia MCI and mild VCI (M-
VCI/MCI-vas) [29]. Each is analogous to the concept of MCI
in terms of stage. However, similar to MCI, VCIND and its
component states lack consistent standardised indicators (for
example, symptoms) and a unique case definition.
Whether within VCIND there is a state predictive of dementia
is largely unknown. Commonly, VCIND is not seen as a pre-
clinical dementia state. Where longitudinal outcome across
the spectrum of VCI has been investigated, progression is
not always clinical (that is, decline/dementia), with many
cases improving or remaining stable at follow-up [9,33-35].
Predictive ability may depend on the nature of the vascular
disturbance in addition to methodological factors (for
example, case description, sample and nature of cognitive
impairment). As with MCI, terminology and diagnostic criteria
for VCIND have not been harmonised, making cross-study
comparison of disease outcomes difficult. Yet unlike MCI, in
which algorithms have been created for each different
classification [10], no such algorithm yet exists for VCIND
and its many possible subtypes.
Defining the boundary between VCIND and MCI
Some MCI classifications do not consider possible vascular
contributing factors to cognitive impairment, and therefore the
distinction between MCI and VCIND becomes blurred [36].
This raises questions of the benefit in distinguishing MCI from
VCIND and whether formulating a new diagnostic category
such as VCIND is even necessary. Whether vascular disease
is considered in the diagnosis of MCI may influence general
population prevalence estimates and longitudinal patterns of
progression. Empirical evidence as to the degree of co-
morbidity across different pathologies (including, for example,
AD and VaD pathologies) will help new classifications,
particularly as biomarkers of specific pathologies emerge.
Generally, the differential diagnosis between MCI and VCIND
is clinical and based on the distinction between AD and VaD.
AD is characterised by a steady and progressive loss of
memory and cognitive faculties, including language
deterioration, impaired visuospatial skills and poor judgement
[37]. AD has a distinct neuropathological pattern of beta-
amyloid plaques and neurofibrillary tangles [38,39]. Other
significant correlates of cognitive decline include synaptic
loss, neuronal death and disruption to the cholinergic
pathway [40]. In contrast, the disease course of VaD is highly
variable, generally following a stepwise pattern of decline and
fluctuating course [41,42]. For a diagnosis of VaD, it is
recommended that radiographic features of vascular disease,
including evidence of an ischaemic lesion, white matter
hyperintensities and/or hypometabolism, be confirmed [37].
However, in some cases, AD and VaD have been found to
result in similar cognitive, functional and behavioural distur-
bances, and frequently both pathologies co-occur [43-45].
AD and VaD may share associated risk factors (stroke,
arterial hypertension, increasing age and low educational
attainment), structural changes, neuropathological profiles
(white matter lesions and apoptosis) and neurochemical
changes (that is, in the cholinergic system) [46]. Overlap may
also result from the large degree of silent risk pathology in
older people.
In older people, multi-morbidity is common and a strict dicho-
tomisation between degenerative and vascular dementing
disorders at both pre-clinical and dementia stages is difficult
to undertake, possibly artificial and perhaps not the most
useful approach. Below, we explore the cognitive, neuro-
imaging and neuropathological profiles of MCI and VCIND to
determine whether evidence exists for the separation of both
conditions.
Cognitive differences (MCI with vascular disease versus
MCI without vascular disease)
Neuropsychological studies have identified attentional-
executive deficits and psychomotor slowing, with relatively
preserved language and recognition memory in individuals
with vascular disease [47,48]. However, not all studies
agree on the importance of each cognitive domain and no
single deficit or pattern of deficits as yet accurately signals
an underlying vascular cause [49]. This is not unexpected
given the multiplicity of aetiologies for vascular disease and
the fact that the pattern and extent of cognitive deficits
would likely reflect not only disease type, but also its severity
[50,51]. For example, cognitive impairment as a conse-
quence of stroke would likely depend on not only timing and
the anatomical location of the stroke, but also the laterality,
severity and extent of the lesion. Furthermore, impairments in
attention and executive and motor function are not
necessarily restricted to vascular causes of dementia and
have also been associated with Lewy body dementia [52]
and fronto-temporal dementia [53].
Where VCIND has been followed longitudinally, cognitive
impairment associated with memory (free and cued recall)
and category fluency was found to predict risk of incident
dementia [54]. These findings suggest that the pattern of
impairment in VCIND conforms more to AD than to VaD.
Indeed, almost half of the cases progressed to AD or mixed
AD at 5 years of follow-up. However, whether these findings
extend across the different vascular causes of VCIND (that is,
stroke- versus hypertension-related cognitive impairment) and
other cognitive domains (that is, perception and motor
performance) remains to be tested.
Available online http://alzres.com/content/1/1/4
Page 3 of 9
(page number not for citation purposes)With regard to MCI, no consistent cognitive profile exists
across the many different case definitions. The focus of MCI
is predominantly impaired memory, but deficits in other
cognitive domains will also be observed when, by definition,
they are also included [55]. Subdivisions between different
cognitive subtypes of MCI (for example, amnestic versus non-
amnestic and single- versus multi-domain) have implications
for inference about aetiology and outcomes. Indeed, while
A-MCI [15,16,56] is thought to be a precursor of AD, non-
amnestic subtypes of MCI have been found to identify
individuals at high risk of both AD and VaD [57].
Where the cognitive profile of individuals with MCI and co-
morbid vascular disease has been compared with that of
individuals with MCI and no vascular disease, group
differences have been reported in some [58,59], but not all
[60], studies. Where differences have been observed, the
MCI vascular group shows more extensive cognitive impair-
ment primarily in speed, attention and executive function [58],
consistent with the general pattern of cognitive difficulties
resulting from vascular disease alone [29]. In other studies,
vascular pathology in MCI (for example, white matter lesions)
has been associated with decreased risk of progression of
cognitive pathology and a more stable cognitive change
profile [61,62], although this is not always replicated [63].
These findings suggest a complex relationship between
vascular disease and cognitive progression in MCI which
might relate to the specific vascular disease factor. Of impor-
tance is determining whether the presence of vascular
disease accelerates or intensifies the cognitive disturbance in
all cases of MCI and which factors might mediate this
relationship (for example, age and reserve). The specific type
of cognitive impairment associated with vascular disease
needs to be defined and measures that are sensitive, specific
and appropriate for longitudinal and observational assess-
ment of cognition in the context of vascular disease (that is,
memory versus non-memory domains) need to be identified in
order to facilitate the development of diagnostic criteria for
cognitive decline in the presence (VCIND) versus the
absence (MCI) of vascular disease.
Neuroimaging profile (MCI versus VCIND)
Neuroimaging in VCIND shows a pattern of vascular lesions
that are similar to, but less severe than, changes observed in
VaD [64]. Pathology includes evidence of leukoaraiosis and
white matter infarction [28,65,66], with mild hippocampal and
enthorhinal cortex atrophy relative to the level seen in MCI/AD
[64]. In contrast, neuroimaging in MCI generally shows a
pattern of changes similar to that observed in AD, namely
temporal and hippocampal atrophy, reduction in whole-brain
glucose metabolism and white matter degeneration, including
hyperintensities and white matter lesions identified using
diffusion tensor imaging [67-74]. Development of dementia
from MCI has been associated with hippocampal volume
changes [69,75-79], medial temporal lobe atrophy [80] and
metabolic alteration [78,81].
Although neuroimaging studies of VCIND and MCI suggest
different pathological processes, findings are not always
consistent and such changes are imperfect predictors of
disease. Considerable intra-individual variation exists, and
overall, neuroimaging-identified abnormalities correlate poorly
with cognitive profile [43]. Indeed, such changes have also
been observed in individuals who do not exhibit cognitive
deficits, raising questions about the uniqueness of findings
[82]. Inconsistency in results possibly arises due to differ-
ences in the use of subjective visual rating scales to assess the
extent of pathology across groups, regional focus of disease
(global versus focal), in addition to differences in enrolment
criteria and the type and severity of vascular disease across
imaging cohorts. Indeed, different vascular disease factors are
associated with varying types and levels of pathology:
hypertension has been associated with reduced cerebral blood
flow [83] and an increased risk of periventricular white matter
lesions [84,85]; lower arterial oxygen saturation and chronic
obstructive pulmonary disease have been associated with
cerebral white matter lesions, but not lacunar infarcts [86];
diabetes has been associated with cortical and hippocampal
atrophy [87,88], white matter lesions [89] and lacunar infarcts
[89]; and current smoking status, diabetes and hypertension
are associated with both neurodegenerative (that is, decreased
brain volume) and vascular (that is, lacunar infarcts and white
matter lesions) changes [90].
The severity and type of lesions required for a diagnosis of
MCI and VCIND remain controversial. Vascular disease and its
risks are associated with brain changes but the clinical
relevance of such changes in the prediction of cognitive
decline and dementia progression remains uncertain. Isolating
unique disease effects from the effects of ageing and other
risk factors (that is, genetic susceptibility) will be important in
determining cellular/molecular/functional vulnerability as a
consequence of vascular disease as well as establishing with
accuracy those changes that distinguish who will and will not
develop cognitive decline and subsequent dementia.
Neuropathology profile (MCI versus VCIND)
The neuropathological profile of MCI has been derived mainly
from a relatively small number of studies with MCI defined
predominately using the A-MCI subtype. Compared with
highly selected controls, MCI cases generally show an
increase in neurofibrillary tangle pathology in memory-related
cortical regions, including the entorhinal cortex, fusiform
gyrus and temporal pole [91,92]. These changes are thought
to represent one of the earliest pathological substrates of this
condition [93] and have been taken to suggest that many
MCI cases are early or prodromal AD [94,95]. Vascular
pathology has also been reported in MCI such that the
neuropathology of some cases includes features associated
with both AD and VaD [96]. However, there is considerable
heterogeneity in findings and not all individuals with MCI at
death or those who progress from MCI to dementia have
been reported to show any particular neuropathology [97].
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Inconsistency in outcome may arise from differences in study
population (for example, specialised clinic versus population),
age group differences (that is, young-old versus old-old),
operational definition of MCI and neuropathological criteria (for
example, Khachaturian, Consortium to Establish a Registry for
Alzheimer’s Disease, or National Institute on Aging-Reagan).
Whether there is a consistent neuropathological profile
across the spectrum of vascular causes and severity levels of
VCI is unknown but seems unlikely. Indeed, VCI is a multi-
factor disorder related to a wide variety of lesions and causes
and as such the pathological profile, similarly to the psycho-
logical and radiological profiles, would be expected to be
heterogeneous. In autopsy studies, an increased prevalence
of cerebral vascular pathology has been found in individuals
with stroke [98], diabetes mellitus [99,100], angina (with co-
morbid dementia) [101,102] and hypertension [103].
Pathological features have included large- and small-vessel
disease, gliosis, microvascular brain damage (severe cribri-
form change), white matter damage, microinfarction and
haemorrhage [104]. Cardiovascular risk factors have also
been associated with AD-like neuropathological lesion
formation in some, but not all, studies, with the extent of
pathology typically being more severe in APOE (apo-
lipoprotein E) e4 carriers [100,103,105-107]. In contrast, in
other cases, an inverse association between vascular disease
and the extent of cerebral degenerative pathology has been
found [101]. The profile of pathology across the different
vascular disease factors is heterogeneous and the
significance of such changes in the development of cognitive
impairment is not known. Furthermore, neuropathological
associations appear to be risk factor-specific and population-
specific, being absent when vascular disease is assessed
using composite cerebrovascular index scores and in non-
Caucasian populations [108,109].
Across the spectrum of age-associated brain changes, no
neuropathological profile yet exists that reliably distinguishes
impairment of different severity levels and causes. In the
general population, currently identifiable pathological features
have not been found to correlate well with observed clinical
and cognitive profiles: many non-demented healthy controls
also show evidence of pathological brain changes associated
with both AD and VaD [43,110,111]. Techniques that better
characterise the impact of vascular disease on brain structure
and more sensitive measures for accurately staging cognitive
status which incorporate known risk factors are needed for
diagnostic differentiation between an at-risk and a not at-risk
brain. However, as with AD, expecting neuropathology to be
a gold standard at any given age for the diagnosis of VCI is
an oversimplification [112].
Vascular risk factor control
Current pharmacological and non-pharmacological modifica-
tions of vascular disease and its risks have been found to
have only a marginal effect on reducing dementia prevalence
in the general population [113]. Indeed, most strategies,
whether pharmacological or non-pharmacological, are
ineffective in the prevention of dementia and are potentially
harmful. With regard to MCI, while pharmacological and
lifestyle modifications have been found to be effective in
ameliorating cognitive impairment in selected older cohorts
[114,115], no consistently positive results have emerged
from randomised controlled trials for such manipulation in the
prevention of MCI or future dementia progression in older
people in the general population [116,117]. Where the
primary prevention of VCIND has been considered, physical
activity has been found to reduce the risk of VCIND in
women, but not men [118]. Why gender differences emerged
in this study is unclear but is thought to be linked to gender
reporting bias in physical activity levels or to statistical error
(type 2 error) due to the small number of male cases.
However, before recommendations based on this result can
be made, it must be replicated in population-representative
samples using objective measures of physical activity.
Overall, the results of intervention trials of vascular risk
reduction on the prevention of cognitive decline and
dementia have not been encouraging so far. There are, how-
ever, other reasons why cardiovascular and cerebrovascular
disease should be prevented and treated, especially for the
prevention of recurrent stroke and hypertension, which
themselves are strong risk factors for functional impairment
and mortality [119]. Further trials are needed to determine
whether the manipulation of different vascular diseases and
vascular risk factors prevents VCIND and dementia progres-
sion. However, it is unlikely that a single strategy will cure or
prevent all dementia; rather, early treatment may require a
combination of therapies with different targets and time
frames for instigation (that is, early, mid- and later life).
Future directions
A more complete understanding of the relationship of vascular
disease to cognitive decline and dementia risk is needed.
Even when vascular pathology appears to be the main under-
lying process, the effect can be heterogeneous, with diverse
neuropsychological, clinical, radiological and morphological
profiles, often in the presence of other pathologies. To date,
the risk of dementia progression cannot yet be accurately
predicted from pre-dementia states captured in the concepts
of MCI and VCIND. Cognitive decline can also occur prior to
vascular insult (for example, pre-stroke dementia), raising the
question of causality [1]. How vascular disease relates to
dementia and its influence across an individual’s life span and
the unique and interactive mechanisms of action on
neurodegeneration must be investigated further to identify the
best treatment and preventative target.
Conclusions
Before case screening for individuals at high risk of dementia
secondary to vascular disease can be undertaken, the
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criteria and validation as a pre-clinical state that confers high
dementia risk in both clinical and population-based studies.
Many questions remain open, particularly with regard to
identifying where the state of VCIND begins and ends. This
review suggests that cognitive change would be expected to
be influenced by vascular disease type and severity, disease
onset, co-occurring factors, underlying vulnerability (for
example, age, education and genetics) and whether patho-
logy occurs secondary to another process (for example, AD).
Accurate early detection of the general population at
increased risk of dementia is central for the implementation of
interventions to prevent dementia and other memory-related
problems in older individuals.
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